Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
Discontinued
Reference number: GID-TA10221
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of nivolumab for untreated advanced hepatocellular carcinoma.
Please note that following on from information received from the company, NICE has decided to suspend this appraisal from its current work programme. The timelines for this appraisal are to be aligned with the latest regulatory expectations and further information regarding the scheduling of this appraisal will be available in due course.
NICE will continue to monitor any development and will update interested parties as and when the situation changes.